Drugs for cancer and HIV infection tend to be safety acceptable., marketing of the drug could be admitted to the market on the basis of results from approved early, Observations in a few patients or even phase 2 trials. Assessing the benefit-risk balance a n » * * . . . -1 trial" theoretically would suffice for registrawith phase 2 trials often is difficult-the effect of the tion if the action of the drug is impressive. This drug is usually temporary; the correlation between situation, however, is rare. Although several classes of response or improvement of clinical measurements drugs have high "cure rates" (fluoroquinolones in and the patient's wellbeing is often poor; and the side urinary tract infections, omeprazole and H2-receptor effects of drugs for these fatal diseases are serious, antagonists in peptic ulcer disease, for example), most Therefore, although sometimes difficult to conduct, drug regulating authorities have not registered them comparative trials that use standard treatment, without comparative trials. placebos, or best supportive care remain the corner stone for reliably assessing the benefit-risk balance.
Should other criteria be applied in fatal diseases? My answer is no, because especially in cancers and HIV infection, the benefit:risk ratio is much more difficult
The common criterion of drug regulatory committees to assess than in other diseases, for registration of a drug is that efficacy and safety have been shown in extensive pharmaceutical, pharmaco logical, toxicological, and clinical studies. Usually the Is treatment efficacious or beneficial? clinical aspects of a drug are studied in phase 1,2, and 3
In cancer or HIV infection it is very difficult to trials, but whether all three phases are necessary for the conclude whether a drug is efficacious or whether the registration of drugs for cancer and HIV infection is a treatment offers benefit to the patient. Most advanced matter of debate in Europe and the United States. malignancies and HIV infection cannot yet be cured The media, the pharmaceutical industry, and the with drug treatment. Mostly, the effect of the drugs is patients involved all put pressure on the drug temporary; and best, death is postponed. regulatory authorities to accelerate the procedures and Cure is an unrealistic requirement for registration of to relax the criteria for admitting oncolytics and drugs oncolytic agents or drugs used in HIV infection, and against HIV infection to the market. They argue that the criteria for efficacy of these drugs have already been the three phases of clinical trials are time consuming loosened. In the treatment of cancer the efficacy of and may withhold a potentially valuable drug from the a drug is determined by the number of patients respondpatient for too long, and that this requirement is ing (complete or partial disappearance of the tumour), therefore not ethical. They advocate early registration duration of response, disease free interval, and the if it appears from phase 2 trials that a tumor is increase in survival. The effect of any cytostatic drug responding and the outcome of the patients is better depends on the nature and extent of the particular than that of historical controls; for such drugs phase 3 malignancy, and in most advanced malignant diseases trials, in which the drug is compared with standard only 25-30% of patients may respond to the drug. treatment, placebo, or untreated controls, can be omitted or done after marketing. They also say that drugs for HIV infection should be available as soon as are clinically relevant depends on the definitions of a com-Survival, although better than in untreated patients, seldom exceeds one or two years. Whether these figures possible--for instance, if a surrogate end points has been shown.
influence on response, the proportion of patients t plete response, and the implications of a complete In the United States and some European countries response in the course of the disease. Such figures the authorities tend to allow early registration of drugs should not be underestimated, but such percentages to treat fatal diseases and consider a positive outcome would be unacceptably low for registration of drug in phase 2 trials or a favourable effect on surrogate end treatments in many other diseases. points sufficient to authorise marketing. An accelerated
Examples are numerous: at present relatively low approval may, however, come into conflict with the response percentages and a limited increase in survival main task of the drug regulatory authorities: to assess can be achieved with registered treatments for the benefit-risk ratio of a drug. In contrast with the malignancies of the gastrointestinal tract the reference treatment depends on whether there is a standard treatment for the disease. If not-in patients with an advanced malignancy who have already received extensive treatment, or when the drug is used as second line treatment-the reference treatment should consist of placebo and best supportive care.
Many supportive measures,H such as transfusions, haematopoietic growth factors, analgesics, antimicro bials, antiemetics, and even corticosteroids,15 may influence the quality of life favourably; best support
ive care is therefore justified as reference treatment. Such trials may be difficult to perform. The ethics of using a placebo arm in a fatal disease is disputed in some countries,1''17 and many physicians and patients survival, and the course of surrogate measures (CD4 will be reluctant to participate because of high (often counts, virus RNA, p24 antigen). The therapeutic gain unrealistic) expectations of new drugs. One solution of the currently marketed antiretrovirus drugs is would be to incorporate patients' preferences in the limited.* The increased survival of patients with AIDS randomisation.18 A comparison with historical controls taking zidovudine, a drug that was compared with may seem easier to perform, but problems arise in interpreting results-in particular, there may be differences in patient characteristics, criteria for placebo, is temporary and relatively short lasting. Didanosine and zalcitabine are registered in several countries for treating patients with AIDS who cannot response, accuracy in the disease staging, and the use tolerate zidovudine or no longer respond to it, but it is of supportive measures and drugs.19 doubtful whether morbidity and survival are greatly Placebo controlled trials might be avoided by improved. These drugs were admitted to the market performing carefully designed dose finding studies, mainly because of their favourable effect on surrogate looking for the dosage that has the lowest toxicity but is measures, but it has become clear that such an effect is poorly correlated with clinical o u tco m e.10 T oxic effects still effective. These trials are not easy to perform with cytotoxic drugs or antimicrobial drugs. Dosage of a cytotoxic drug is often based on the maximum tolerable dosage (found in phase 1 studies) and that of antimicrobial drugs comes from in vitro susceptibility The second reason why benefit is more difficult to studies. assess for oncolytic treatment and in HIV infection is that the drugs are often toxic; neutropenia, gastro intestinal side effects, alopecia, mucositis, neuropathy, or (in case of didanosine) the risk of pancreatitis, as
Conclusions
In cancer, HIV infection, and possibly other fatal well as frequent hospital admissions for complications diseases, comparative trials either with placebo or with of treatment (such as infectious episodes and the need best supportive care seem to be inevitable for a reliable for blood transfusions), may affect the quality of life of assessment of the benefit-risk ratio. The drug the patient and should be set against the temporary regulating authorities could themselves be helpful in effect. Furthermore, the action of a particular drug is harder to interpret when more than one cytotoxic drug is given or when antimicrobial agents are also used. making clear to the public that, especially in these diseases, such trials, although time consuming, the best guarantee against drugs being registered too Of course, one also cannot conclude automatically early and possibly being a disappointment afterwards. that a drug with a limited effect, which prolongs life only slightly and possesses many side effects, is not valuable for a patient. For instance, the detrimental impact of the side effects of chemotherapy for advanced breast or colon cancer on the quality of life of cancer patients seems to be less than expected.1112 These data cannot, however, be generalised to all cyto static treatments.
Whether the treatment is beneficial depends on the definitions of response. When response is correlated with benefit or obvious palliation, improvement of the patient's general condition, or improvement in symptoms, this should be taken into account. Particu larly in phase 2 trials, however, either this is not the case or the correlation between response and clinical symptoms is vague.
Wellbeing of the patient
Before a marketing authorisation is delivered, studies of the impact of the treatment on the patient's wellbeing should be required. One approach is to investigate the influence of the drug on simple clinical symptoms or laboratory markers associated with the malignant disease or HIV infection (fatigue, body weight, pain, dyspnoea, anaemia, anorexia, etc); another is to formally assess quality of life with validated questionnaires."
Comparative trials seem most appropriate, as the absence of a control group makes a reliable assessment (figure)
